Rabies virus binding to an acetylcholine receptor α‐subunit peptide
The DOI matches its Crossref record.
Abstract
The binding of 125 I‐labeled rabies virus to a synthetic peptide comprising residues 173–204 of the α1‐subunit of the nicotinic acetylcholine receptor was investigated. Binding of rabies virus to the receptor peptide was dependent on pH, could be competed with by unlabeled homologous virus particles, and was saturable. Synthetic peptides of snake venom, curaremimetic neurotoxins and of the structurally similar segment of the rabies virus glycoprotein, were effective in competing with labeled virus binding to the receptor peptide at micromolar concentrations. Similarly, synthetic peptides of the binding domain on the acetylcholine receptor competed for binding. These findings suggest that both rabies virus and neurotoxins bind to residues 173–204 of the α1‐subunit of the acetylcholine receptor. Competition studies with shorter α‐subunit peptides within this region indicate that the highest affinity virus binding determinants are located within residues 179–192. A rat nerve α3‐subunit peptide, that does not bind α‐bungarotoxin, inhibited binding of virus to the α1 peptide, suggesting that rabies binds to neuronal nicotinic acetylcholine receptors. These studies indicate that synthetic peptides of the glycoprotein binding domain and of the receptor binding domain may represent useful antiviral agents by targeting the recognition event between the viral attachment protein and the host cell receptor, and inhibiting attachment of virus to the receptor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Extracellular vesicles: biology and emerging therapeutic opportunities
EL Andaloussi, S., Mäger, I., Breakefield, X. O., & Wood, M. J. A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3978 · Cited by 3,571
Transvascular delivery of small interfering RNA to the central nervous system
Kumar, P., Wu, H., McBride, J. L., Jung, K.-E., Hee Kim, M., Davidson, B. L., Kyung Lee, S., Shankar, P., & Manjunath, N. (2007) · Nature · doi:10.1038/nature05901 · Cited by 1,246
Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy
Lee, Y., EL Andaloussi, S., & Wood, M. J. A. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds317 · Cited by 938
Exosome-mediated delivery of siRNA in vitro and in vivo
El-Andaloussi, S., Lee, Y., Lakhal-Littleton, S., Li, J., Seow, Y., Gardiner, C., Alvarez-Erviti, L., Sargent, I. L., & Wood, M. J. A. (2012) · Nature Protocols · doi:10.1038/nprot.2012.131 · Cited by 601
Exosomes for targeted siRNA delivery across biological barriers
EL Andaloussi, S., Lakhal, S., Mäger, I., & Wood, M. J. A. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.08.008 · Cited by 539
Mazarakis, N. D. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.19.2109 · Cited by 426
Targeting Receptor-Mediated Transport for Delivery of Biologics Across the Blood-Brain Barrier
Lajoie, J. M., & Shusta, E. V. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124852 · Cited by 399
Exosome-based small RNA delivery: Progress and prospects
Lu, M., Xing, H., Xun, Z., Yang, T., Ding, P., Cai, C., Wang, D., & Zhao, X. (2018) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2017.07.008 · Cited by 97
Lentiviral vectors for ocular gene therapy
Arsenijevic, Y., Berger, A., Udry, F., & Kostic, C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081605 · Cited by 47
Metadata
- Authors
- Lentz, T. L.
- Venue
- Journal of Molecular Recognition
- Publisher
- Wiley
- Published
- 1990-04
- Volume
- 3
- Issue
- 2
- Pages
- 82-88
- ISSN
- 0952-3499 (ISSN-L)
- 1099-1352
- OpenAlex
- W1978227190
- Cited by
- 92
- References
- 0
- FWCI
- 0.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.